Loading...
Loading...
ENVB| Name | Value |
|---|---|
| Revenues | 647.1K |
| Cost of Revenue | 84.7K |
| Gross Profit | 562.4K |
| Operating Expense | 2,299.7K |
| Operating I/L | -2,384.4K |
| Other Income/Expense | -1,029.3K |
| Interest Income | 0.6K |
| Pretax | -3,413.6K |
| Income Tax Expense | 22.3K |
| Net Income/Loss | -3,435.9K |
Enveric Biosciences, Inc. is a pharmaceutical company specializing in the development of cannabinoid medicines for cancer care. The company's product pipeline includes EV104 for osteoarthritis, EVM-101 and EVM-201 for cancer-related distress, EVM-301 for mental health indications, EV102, a cannabinoid cream for topical skin application, and EV101, a cannabinoid and chemotherapy combination therapy.
